A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients

作者：Yokoyama Keitaro^*; Fukagawa Masafumi; Shigematsu Takashi; Akiba Takashi; Fujii Akifumi; Odani Motoi; Akizawa Tadao

来源：Clinical Nephrology, 2017, 88(2): 68-78.

DOI：10.5414/CN108974

• calcium-sensing receptor agonist (calcimimetics)
• etelcalcetide (ONO-5163/AMG 416)
• secondary hyperparathyroidism
• clinical trial

Aims: To evaluate doseescalation of etelcalcetide (ONO-5163/ AMG 416), a novel, intravenous (IV), longacting calcium-sensing receptor agonist, for treatment of secondary hyperparathyroidism (SHPT) in Japanese hemodialysis patients. Materials and methods: In this multicenter study, IV injections of etelcalcetide (3 times a week for 12 weeks) were administered, with dose escalation every 4 weeks depending on changes in serum intact parathyroid hormone (iPTH) and corrected calcium (cCa). A total of 24 patients participated in this study. Results: Serum iPTH was reduced in a time-and dose-dependent manner, with reductions (in pg/mL) at 12 weeks of -226.1 +/- 125.3, -362.5 +/- 161.5, and -412.4 +/- 130.2, respectively, for maximum doses of 5, 10, and 15 mg. At the end of the treatment, 50% of patients had serum iPTH levels within the target range (60 - 240 pg/mL). Serum cCa and phosphorus were reduced in parallel with iPTH. Adverse events (AEs) occurred in 20 patients (83.3%). The most frequently observed AEs (> 10%) were either mild or moderate nasopharyngitis (29.2%), decreased serum calcium (16.7%), and vomiting (12.5%). Conclusions: Dose-escalated triweekly etelcalcetide was effective for SHPT in Japanese hemodialysis patients and was satisfactorily tolerated.

• 出版日期2017-8